Navigation Links
Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
Date:12/11/2007

a nephrotoxic agent. ATRIPLA may cause fetal harm when administered during the first trimester to a pregnant woman. Women should not become pregnant or breast-feed while taking ATRIPLA. Barrier contraception must always be used in combination with other methods of contraception (eg, oral or other hormonal contraceptives). If the patient becomes pregnant while taking ATRIPLA, she should be apprised of the potential harm to the fetus.

Mild-to-moderate rash is a common side effect of efavirenz. In controlled clinical trials, 26% of patients treated with efavirenz experienced new-onset skin rash compared with 17% of patients treated in control groups. ATRIPLA should be discontinued in patients developing severe rash associated with blistering, desquamation, mucosal involvement, or fever. Skin discoloration, associated with emtricitabine, may also occur.

Liver enzymes should be monitored in patients with known or suspected hepatitis B or C and when ATRIPLA is administered with ritonavir or other medications associated with liver toxicity.

Decreases in bone mineral density (BMD) have been seen with tenofovir DF. Cases of osteomalacia (associated with proximal renal tubulopathy) have been reported in association with the use of tenofovir DF.

Use ATRIPLA with caution in patients with a history of seizures. Convulsions have been observed in patients receiving efavirenz, generally in the presence of known medical history of seizures.

Redistribution/accumulation of body fat has been observed in patients receiving antiretroviral therapy.

Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including the components of ATRIPLA.

Saquinavir should not be used as the only protease inhibitor in combination with ATRIPLA.

Coadministration of ATRIPLA and atazanavir is not recommended due to concerns regarding decreased atazanavir concentrations. Atazanavir and lopinavir/rito
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Bristol-Myers Squibb, New Jersey Childrens Hospital Launch Center for Immune System Disorders & Infectious Diseases Including HIV/AIDS
2. Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations
3. PARIs eFlow Included in Gileads NDA Submission for Aztreonam Lysine for Inhalation
4. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
5. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
6. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
7. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
8. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
11. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)...  Misonix, Inc. (NASDAQ: MSON ), an ... markets innovative therapeutic ultrasonic products for spine surgery, ... surgery and other surgical applications, announced today that ... quarter fiscal year 2015 on Thursday, May 7, ... that same day, Thursday, May 7, 2015, at ...
(Date:5/1/2015)... N.J., May 1, 2015 Cambrex Corporation (NYSE: ... 31, 2015. Highlights , Sales ... increased 27% excluding foreign currency impact, driven by Innovator products ... from $8.4 million in the first quarter of 2014. ... $0.04 in the first quarter last year and Adjusted Diluted ...
(Date:4/30/2015)... 30, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: ... a focus on Omega-3 therapies for cardiovascular disease ... and financial results for the fiscal year ended ... are in Canadian dollars unless otherwise stated. ... with the right strategic partners and additional capitalization ...
Breaking Medicine Technology:Misonix, Inc. To Report Third Quarter Fiscal Year 2015 Financial Results On Thursday, May 7, 2015 2Cambrex Reports First Quarter 2015 Financial Results 2Cambrex Reports First Quarter 2015 Financial Results 3Cambrex Reports First Quarter 2015 Financial Results 4Cambrex Reports First Quarter 2015 Financial Results 5Cambrex Reports First Quarter 2015 Financial Results 6Cambrex Reports First Quarter 2015 Financial Results 7Cambrex Reports First Quarter 2015 Financial Results 8Cambrex Reports First Quarter 2015 Financial Results 9Cambrex Reports First Quarter 2015 Financial Results 10Cambrex Reports First Quarter 2015 Financial Results 11Pivotal Therapeutics Announces 2014 Financial Results 2Pivotal Therapeutics Announces 2014 Financial Results 3Pivotal Therapeutics Announces 2014 Financial Results 4Pivotal Therapeutics Announces 2014 Financial Results 5Pivotal Therapeutics Announces 2014 Financial Results 6
... 25, 2011 Angelini Labopharm, LLC, today ... Company.  Formerly Senior Vice President, Sales and Marketing for ... subsidiary, Labopharm USA, Inc., Ms. Heino,s primary focus will ... the commercialization of OLEPTRO™, as well as to explore ...
... N.J., Jan. 25, 2011 Johnson & Johnson (NYSE: ... the fourth quarter of 2010, a decrease of 5.5% as ... 5.1% and the negative impact of currency was 0.4%. Domestic ... operational decline of 2.3% and a negative currency impact of ...
Cached Medicine Technology:Angelini Labopharm Confirms Appointment of Mary Anne Heino as President 2Angelini Labopharm Confirms Appointment of Mary Anne Heino as President 3Johnson & Johnson Reports 2010 Fourth-Quarter and Full-Year Results 2Johnson & Johnson Reports 2010 Fourth-Quarter and Full-Year Results 3Johnson & Johnson Reports 2010 Fourth-Quarter and Full-Year Results 4Johnson & Johnson Reports 2010 Fourth-Quarter and Full-Year Results 5Johnson & Johnson Reports 2010 Fourth-Quarter and Full-Year Results 6Johnson & Johnson Reports 2010 Fourth-Quarter and Full-Year Results 7Johnson & Johnson Reports 2010 Fourth-Quarter and Full-Year Results 8Johnson & Johnson Reports 2010 Fourth-Quarter and Full-Year Results 9Johnson & Johnson Reports 2010 Fourth-Quarter and Full-Year Results 10Johnson & Johnson Reports 2010 Fourth-Quarter and Full-Year Results 11Johnson & Johnson Reports 2010 Fourth-Quarter and Full-Year Results 12Johnson & Johnson Reports 2010 Fourth-Quarter and Full-Year Results 13Johnson & Johnson Reports 2010 Fourth-Quarter and Full-Year Results 14
(Date:5/3/2015)... CA (PRWEB) May 03, 2015 NuevaCare ... MnemeTherapy® at two upcoming area seminars. The first event ... PSA Annual Regional Stroke Conference to be held at ... offered on Wednesday, May 13 during the Dementia Conference ... , “These seminars offer an excellent opportunity to ...
(Date:5/3/2015)... 2015 HealthPostures, a pioneering ergonomics ... its appearance at the , May 5 - 7, ... will exhibit at the conference include its bestselling TaskMate ... solutions is the 6100 TaskMate Executive. Features of the ... adjustable keyboard tray, extended platform work surface and supply ...
(Date:5/2/2015)... BC (PRWEB) May 02, 2015 Vancouver fencing ... will now provide valuable advice to prospective clients related to ... are looking to install railings around their decks and patios. ... several questions that pop up once the person rolls up ... phases of installing a railing in finding a gate that ...
(Date:5/2/2015)... York, NY (PRWEB) May 02, 2015 ... when a deadly natural disaster strikes anywhere on this ... to leverage human sympathy and compassion for their own ... (United States Computer Emergency Readiness Team) issued an ... users “of potential email scams citing the earthquake in ...
(Date:5/2/2015)... On Tuesday April 7th, the patient ... to celebrate improvements in patient care. In 2014 the ... had zero acquired ventilator associated infections, zero central line ... was also recently named a Top Performer by the ... credited the teamwork of staff from all departments involved ...
Breaking Medicine News(10 mins):Health News:NuevaCare Introduces MnemeTherapy® Approach to Care for Elderly Patients with Alzheimer’s, Stroke and Other Types of Neurodegenerative Conditions 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 3Health News:Professional Staff at QS Fencing Company Now Provides Advice on Railings and Gates 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 3Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 4Health News:East Liverpool City Hospital Celebrates Patient Care Improvements 2
... An elevated rate of increase in prostate specific antigen (PSA) ... prostate cancer, according to a new study published in the ... rate of PSA increase prior to treatment (PSA Velocity) is ... high risk of death from prostate cancer. ,According ...
... A ten-day long festival for gays began in the capital ... will showcase over 20 films on homosexuality directed by many ... and a photographic presentation. ,The aim of the ... country where Section 377 of the Indian Penal Code (IPC) ...
... has adopted yet another spiritual ploy to keep her out of ... report to Los Angeles' Century Regional Detention Center by June 5, ... Mary. ,In the past few days Paris has been ... DVD called Innocent. ,Some pals feel that Hilton, who ...
... chemotherapy errors identified in children reach patients, according to ... errors in children . Published in the July 1, ... American Cancer Society, the study concluded that the antimetabolite ... errors, and that errors in drug administration and errors ...
... UK have discovered mutations in the DNA of four ... breast cancer in women . ,The discovery ... at higher-than-average risk of breast cancer so that they ... - the age when routine breast screening now begins. ...
... participating in one of the largest ever Parkinson's disease ... creatine can slow the symptom progression of this ... the brain in which patients develop tremor, slowness of ... one million people in the U.S. Currently, there are ...
Cached Medicine News:Health News:Scientists Identify the Most Significant Single Predictor of Aggressive Prostate Cancer 2Health News:Gay Film Festival Begins in Delhi 2Health News:Most Pediatric Chemotherapy Mistakes Reach Patients 2Health News:UK Scientists Identify Gene Mutations That Trigger Breast Cancer 2Health News:UK Scientists Identify Gene Mutations That Trigger Breast Cancer 3Health News:Emory Participates in Study to Slow Progression of Parkinson's Disease 2
... feature powerful, maintenance-free motors, and ... rotors for unparalleled application versatility. ... one: a high capacity general ... a high-speed centrifuge for separating ...
... Rotor has a standard 1.5ml rotor and 6 ... Easy operation (no switches to mess with). Simply ... the plastic tab to open. Starts and stops ... 2000 x g. Only five inches in diameter. ...
... Personal Micro Centrifuges MiniSpin and MiniSpin plus ... they are powerful enough so that each ... centrifuge for a wide range of molecular ... are available to meet your performance requirements. ...
Spectrafuge 16M High speed microcentrifuge. High g-force for molecular biology applications. Brushless, maintenance-free motor. Easy to use control panel. Complete with 18 x 1.5/2.0 ml rotor. StripSp...
Medicine Products: